Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 94

Similar articles for PubMed (Select 22561489)

1.

Contributions of capsule, lipoproteins and duration of colonisation towards the protective immunity of prior Streptococcus pneumoniae nasopharyngeal colonisation.

Cohen JM, Chimalapati S, de Vogel C, van Belkum A, Baxendale HE, Brown JS.

Vaccine. 2012 Jun 22;30(30):4453-9. doi: 10.1016/j.vaccine.2012.04.080. Epub 2012 May 3.

2.

The immunising effect of pneumococcal nasopharyngeal colonisation; protection against future colonisation and fatal invasive disease.

Richards L, Ferreira DM, Miyaji EN, Andrew PW, Kadioglu A.

Immunobiology. 2010 Apr;215(4):251-63. doi: 10.1016/j.imbio.2009.12.004. Epub 2009 Dec 28.

PMID:
20071053
3.

Protective contributions against invasive Streptococcus pneumoniae pneumonia of antibody and Th17-cell responses to nasopharyngeal colonisation.

Cohen JM, Khandavilli S, Camberlein E, Hyams C, Baxendale HE, Brown JS.

PLoS One. 2011;6(10):e25558. doi: 10.1371/journal.pone.0025558. Epub 2011 Oct 7.

4.

Infection with conditionally virulent Streptococcus pneumoniae Δpab strains induces antibody to conserved protein antigens but does not protect against systemic infection with heterologous strains.

Chimalapati S, Cohen J, Camberlein E, Durmort C, Baxendale H, de Vogel C, van Belkum A, Brown JS.

Infect Immun. 2011 Dec;79(12):4965-76. doi: 10.1128/IAI.05923-11. Epub 2011 Sep 26.

5.

Mucosal and systemic immunization with a novel attenuated pneumococcal vaccine candidate confer serotype independent protection against Streptococcus pneumoniae in mice.

Wu K, Yao R, Wang H, Pang D, Liu Y, Xu H, Zhang S, Zhang X, Yin Y.

Vaccine. 2014 Jul 16;32(33):4179-88. doi: 10.1016/j.vaccine.2014.05.019. Epub 2014 Jun 2.

PMID:
24945468
6.
7.
8.

Immune responses to recombinant pneumococcal PsaA antigen delivered by a live attenuated Salmonella vaccine.

Wang S, Li Y, Shi H, Scarpellini G, Torres-Escobar A, Roland KL, Curtiss R 3rd.

Infect Immun. 2010 Jul;78(7):3258-71. doi: 10.1128/IAI.00176-10. Epub 2010 May 17.

9.
10.

Induction of systemic and mucosal immune response and decrease in Streptococcus pneumoniae colonization by nasal inoculation of mice with recombinant lactic acid bacteria expressing pneumococcal surface antigen A.

Oliveira ML, Arêas AP, Campos IB, Monedero V, Perez-Martínez G, Miyaji EN, Leite LC, Aires KA, Lee Ho P.

Microbes Infect. 2006 Apr;8(4):1016-24. Epub 2006 Jan 18.

PMID:
16549380
11.

IgG antibody concentrations after immunization with 11-valent mixed-carrier pneumococcal conjugate vaccine in efficacy trial against pneumonia among Filipino infants.

Soininen A, Nohynek H, Lucero M, Jousimies K, Ugpo J, Williams G, Käyhty H; ARIVAC Consortium.

Vaccine. 2009 May 5;27(20):2680-8. doi: 10.1016/j.vaccine.2009.02.059. Epub 2009 Feb 24.

PMID:
19428879
12.
13.

Mucosal vaccination with a multicomponent adenovirus-vectored vaccine protects against Streptococcus pneumoniae infection in the lung.

Arévalo MT, Xu Q, Paton JC, Hollingshead SK, Pichichero ME, Briles DE, Girgis N, Zeng M.

FEMS Immunol Med Microbiol. 2009 Apr;55(3):346-51. doi: 10.1111/j.1574-695X.2008.00518.x.

14.

Protection against nasal colonization with Streptococcus pneumoniae by parenteral immunization with a DNA vaccine encoding PspA (Pneumococcal surface protein A).

Ferreira DM, Oliveira ML, Moreno AT, Ho PL, Briles DE, Miyaji EN.

Microb Pathog. 2010 Jun;48(6):205-13. doi: 10.1016/j.micpath.2010.02.009. Epub 2010 Mar 4.

PMID:
20206678
15.

Emergence of antibody to capsular polysaccharides of Streptococcus pneumoniae during outbreaks of pneumonia: association with nasopharyngeal colonization.

Musher DM, Groover JE, Reichler MR, Riedo FX, Schwartz B, Watson DA, Baughn RE, Breiman RF.

Clin Infect Dis. 1997 Mar;24(3):441-6.

16.

The potential for using protein vaccines to protect against otitis media caused by Streptococcus pneumoniae.

Briles DE, Hollingshead SK, Nabors GS, Paton JC, Brooks-Walter A.

Vaccine. 2000 Dec 8;19 Suppl 1:S87-95. Review.

PMID:
11163470
17.

Intranasal immunization with recombinant PspA fused with a flagellin enhances cross-protective immunity against Streptococcus pneumoniae infection in mice.

Nguyen CT, Kim SY, Kim MS, Lee SE, Rhee JH.

Vaccine. 2011 Aug 5;29(34):5731-9. doi: 10.1016/j.vaccine.2011.05.095. Epub 2011 Jun 13.

PMID:
21696869
18.

Characterization of antibodies to PspA and PsaA in adults over 50 years of age with invasive pneumococcal disease.

Baril L, Briles DE, Crozier P, King J, Punar M, Hollingshead SK, McCormick JB.

Vaccine. 2004 Dec 21;23(6):789-93.

PMID:
15542203
19.

Effective protection against secondary pneumococcal pneumonia by oral vaccination with attenuated Salmonella delivering PspA antigen in mice.

Seo SU, Kim JJ, Yang H, Kwon HJ, Yang JY, Curtiss Iii R, Kweon MN.

Vaccine. 2012 Nov 6;30(48):6816-23. doi: 10.1016/j.vaccine.2012.09.015. Epub 2012 Sep 18.

PMID:
23000127
20.

The nasal dendritic cell-targeting Flt3 ligand as a safe adjuvant elicits effective protection against fatal pneumococcal pneumonia.

Kataoka K, Fujihashi K, Oma K, Fukuyama Y, Hollingshead SK, Sekine S, Kawabata S, Ito HO, Briles DE, Oishi K.

Infect Immun. 2011 Jul;79(7):2819-28. doi: 10.1128/IAI.01360-10. Epub 2011 May 2.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk